Study Understanding Pre-Exposure pRophylaxis of NOvel Anitbodies (SUPERNOVA)

Haidar et al., NCT05648110, SUPERNOVA, NCT05648110, Jun 2026

42nd treatment shown to reduce risk in May 2022, now with p = 0.026 from 20 studies, recognized in 33 countries. Efficacy is variant dependent.

Lower risk for hospitalization and cases.

No treatment is 100% effective. Protocols combine treatments.

6,600+ studies for 220+ treatments. c19early.org

Meta-analysis

RCT 1,663 immunocompromised patients showing higher mortality with tixagevimab/cilgavimab, without statistical significance. Tixagevimab/cilgavimab may have lost efficacy with variants at the time but retain side effects.

Efficacy is variant dependent. In Vitro research suggests a lack of efficacy for omicron BA.2.75.2, BA.4.6, BQ.1.11, BA.5, BA.2.75, XBB2,3, XBB.1.53, ХВВ.1.9.13, XBB.1.9.3, XBB.1.5.24, XBB.1.16, XBB.2.9, BQ.1.1.45, CL.1, and CH.1.14.

Important missing comments or errors? Let us know.

Study covers AZD5156 and tixagevimab/cilgavimab.

risk of death, 103.6% higher, RR 2.04, p = 0.12, treatment 24 of 1,102 (2.2%), control 6 of 561 (1.1%), all-cause mortality, day 451, registry.

Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates

1. Planas et al., Resistance of Omicron subvariants BA.2.75.2, BA.4.6 and BQ.1.1 to neutralizing antibodies, bioRxiv, doi:10.1101/2022.11.17.516888.biorxiv.org, doi.org.

2. Haars et al., Prevalence of SARS-CoV-2 Omicron Sublineages and Spike Protein Mutations Conferring Resistance against Monoclonal Antibodies in a Swedish Cohort during 2022–2023, Microorganisms, doi:10.3390/microorganisms11102417.mdpi.com, doi.org.

3. Uraki et al., Antiviral efficacy against and replicative fitness of an XBB.1.9.1 clinical isolate, iScience, doi:10.1016/j.isci.2023.108147.sciencedirect.com, doi.org.

4. Pochtovyi et al., In Vitro Efficacy of Antivirals and Monoclonal Antibodies against SARS-CoV-2 Omicron Lineages XBB.1.9.1, XBB.1.9.3, XBB.1.5, XBB.1.16, XBB.2.4, BQ.1.1.45, CH.1.1, and CL.1, Vaccines, doi:10.3390/vaccines11101533.mdpi.com, doi.org.

Haidar et al., 18 Jun 2026, Double Blind Randomized Controlled Trial, placebo-controlled, multiple countries, preprint, 1 author, trial NCT05648110 (history) (SUPERNOVA). Contact: taylor.cohen@astrazeneca.com.